Mesothelioma Stages

Mesothelioma staging is the process of determining the extent of cancer spread in the body, which is essential for selecting the appropriate treatment and estimating prognosis. The staging system for pleural mesothelioma uses the TNM (Tumor, Node, Metastasis) classification established by the American Joint Committee on Cancer (AJCC, 8th edition) and refined by the International Association for the Study of Lung Cancer (IASLC) Mesothelioma Staging Project.¹

A formal TNM staging system exists only for pleural mesothelioma. Peritoneal mesothelioma is assessed using the Peritoneal Cancer Index (PCI) rather than TNM staging, while pericardial and testicular mesothelioma are too rare for formal staging systems to have been developed.²

Most patients with pleural mesothelioma (approximately 60–70%) are diagnosed at stage III or IV because the disease produces few or no symptoms in its early stages. Symptoms such as chest pain, shortness of breath, and pleural effusion typically do not develop until the tumor has grown extensively along the pleural surface — often decades after the initial asbestos exposure. This late presentation significantly limits treatment options and is the primary reason for the disease's poor overall prognosis.¹

Accurate staging requires a combination of imaging studies (CT, PET-CT, MRI) and, in many cases, surgical exploration. Staging determines whether the cancer is resectable (removable by surgery), which systemic treatments are appropriate, and what the expected survival outcomes are.²

Symptoms of mesothelioma correlate with the stage of disease. Understanding this relationship helps explain why most patients are diagnosed at advanced stages:¹

Stage I (Localized)

• Often asymptomatic or associated with mild, nonspecific symptoms
• Mild chest discomfort or occasional shortness of breath with exertion
• Small pleural effusion may be discovered incidentally on imaging for other reasons
• Symptoms are easily attributed to aging, COPD, or other common conditions¹

Stage II (Locally Advanced)

• Increasing shortness of breath and chest tightness
• Moderate pleural effusion causing exercise intolerance
• Persistent dull chest pain, typically unilateral
• Dry cough that does not resolve with standard treatment¹

Stage III (Advanced)

• Significant shortness of breath at rest or with minimal activity
• Large or recurrent pleural effusion requiring repeated drainage
• Chest wall pain from tumor invasion into the ribs and intercostal muscles
• Unexplained weight loss, fatigue, and decreased appetite
• Difficulty swallowing if the tumor involves the esophagus¹

Stage IV (Metastatic)

• Severe dyspnea and respiratory distress
• Severe chest and body pain from metastatic spread
• Profound cachexia (wasting) with significant weight loss
• Symptoms from distant metastases: bone pain, neurological symptoms (brain), jaundice (liver)
• General decline in functional status and quality of life¹

Staging for mesothelioma is performed after the initial diagnosis is confirmed and before treatment decisions are made. Accurate staging requires multiple imaging modalities and, in some cases, surgical exploration:²

Imaging studies for staging

• Contrast-enhanced CT of the chest and abdomen — The primary staging modality. CT evaluates the extent of pleural thickening, tumor invasion of adjacent structures (chest wall, diaphragm, mediastinum), lymph node enlargement, and the presence or absence of distant metastases in the contralateral lung, liver, or adrenal glands.²
• PET-CT (FDG-PET/CT) — Essential for accurate staging. PET-CT detects metabolically active tumor that may not be visible on CT alone, identifies lymph node involvement with greater sensitivity than CT, and detects distant metastases. The SUV (standardized uptake value) on PET also provides prognostic information — higher SUV correlates with more aggressive disease.²
• MRI of the chest — Provides superior soft-tissue contrast for evaluating diaphragmatic invasion, chest wall involvement, and extent of mediastinal invasion. MRI is particularly valuable for surgical planning when EPP or P/D is being considered.²
• Brain MRI — Obtained if brain metastases are suspected based on neurological symptoms, though CNS metastases from mesothelioma are uncommon.²

Surgical staging

• VATS (video-assisted thoracoscopic surgery) — Provides direct visualization of the pleural surfaces and is the most accurate method for assessing T stage (tumor extent). VATS can identify pleural disease that is not visible on imaging and allows simultaneous biopsy.²
• Mediastinoscopy or EBUS (endobronchial ultrasound) — Evaluates mediastinal lymph node involvement (N stage). Pathological confirmation of lymph node status is more accurate than imaging-based assessment alone.²
• Contralateral thoracoscopy — In selected cases, examination of the contralateral pleural space confirms the absence of bilateral disease, which would indicate stage IV.²

Restaging

Restaging is performed after neoadjuvant treatment (chemotherapy or immunotherapy given before surgery) to reassess disease extent and determine whether surgical resection remains feasible. Restaging typically involves repeat CT and/or PET-CT.³

The TNM staging system for pleural mesothelioma (AJCC 8th edition, 2017) classifies the disease into four stages based on three components:⁴

• T (Tumor) — The extent of the primary tumor
• N (Nodes) — The presence and location of lymph node involvement
• M (Metastasis) — The presence or absence of distant metastatic spread

T (Tumor) categories explained:⁴

• T1 — Tumor limited to the ipsilateral parietal pleura, with or without visceral pleural involvement
• T2 — Tumor involving each of the ipsilateral pleural surfaces with at least one of: confluence of visceral pleural tumor, invasion of diaphragmatic muscle, invasion of lung parenchyma
• T3 — Locally advanced but potentially resectable: invasion into endothoracic fascia, mediastinal fat, solitary chest wall focus, or non-transmural pericardial involvement
• T4 — Locally advanced, technically unresectable: diffuse or multifocal chest wall invasion, transdiaphragmatic extension to the peritoneum, invasion of spine, rib, brachial plexus, heart, great vessels, trachea, esophagus, or contralateral pleura

N (Node) categories:⁴

• N0 — No regional lymph node involvement
• N1 — Ipsilateral bronchopulmonary, hilar, or mediastinal lymph nodes involved (including internal mammary, peridiaphragmatic, and intercostal nodes)
• N2 — Contralateral mediastinal or ipsilateral/contralateral supraclavicular lymph nodes involved

M (Metastasis) categories:⁴

• M0 — No distant metastasis
• M1 — Distant metastasis present

Peritoneal mesothelioma staging

Peritoneal mesothelioma does not use the TNM system. Instead, the Peritoneal Cancer Index (PCI) assesses disease extent for surgical planning. The PCI divides the abdomen into 13 regions and assigns a lesion size score (0–3) to each, producing a total score of 0–39. Lower PCI scores indicate more limited disease and better surgical outcomes. PCI ≤10 is generally considered favorable for complete cytoreduction.⁵

Treatment recommendations for mesothelioma are directly guided by the disease stage at diagnosis:³

Stage I–II (Early-stage, resectable)

• Multimodal therapy — The standard approach combines surgery (P/D or EPP) with perioperative chemotherapy (pemetrexed/platinum, typically 2–4 cycles before and/or after surgery) and, in some protocols, adjuvant radiation therapy.³
• Neoadjuvant immunotherapy — Emerging protocols investigate immunotherapy (nivolumab/ipilimumab) before surgery, with the goal of inducing immune-mediated tumor regression to improve surgical outcomes.³

Stage III (Locally advanced, borderline resectable)

• Stage IIIA — May be amenable to surgery as part of multimodal therapy at experienced centers, particularly with epithelioid histology and good performance status.³
• Stage IIIB — Generally not considered surgically resectable. Standard treatment is systemic therapy: nivolumab/ipilimumab or pemetrexed/platinum chemotherapy. Palliative procedures (pleurodesis, indwelling catheter) manage symptoms.³
• Clinical trials — Stage III patients are particularly good candidates for clinical trials testing new treatment combinations.

Stage IV (Metastatic)

• Systemic therapy — Nivolumab/ipilimumab or pemetrexed/platinum chemotherapy (± bevacizumab) as first-line treatment.³
• Palliative care — Pain management, respiratory support, nutritional optimization, and psychosocial support are integral to stage IV management. Early palliative care referral improves quality of life and may also improve survival.
• Palliative procedures — Pleurodesis, indwelling pleural catheter, or thoracentesis for symptomatic effusion. Palliative radiation for pain control at specific sites.³

Stage at diagnosis is one of the most important prognostic factors in mesothelioma. The TNM staging system directly correlates with survival outcomes:⁴

• Stage I — Median survival: 21+ months; 5-year survival: 16–20%. The best outcomes are achieved with multimodal therapy (surgery + chemotherapy ± radiation).⁴
• Stage II — Median survival: 14–19 months; 5-year survival: 10–15%.⁴
• Stage III — Median survival: 10–16 months; 5-year survival: 5–10%.⁴
• Stage IV — Median survival: 6–12 months; 5-year survival: <5%.⁴

Stage interacts with other prognostic factors:

• Cell type — Within each stage, epithelioid histology has better survival than biphasic or sarcomatoid. A stage I sarcomatoid patient may have a worse prognosis than a stage II epithelioid patient.⁴
• Surgical candidacy — Stage I–II patients who receive multimodal therapy with surgery have significantly better outcomes than stage-matched patients treated with chemotherapy alone.⁴
• Treatment center — Patients treated at high-volume specialized centers consistently have better stage-for-stage outcomes than those treated at community centers.³

The poor overall prognosis of mesothelioma is largely a consequence of late-stage diagnosis. If effective screening methods were available to detect the disease at stage I, the overall survival statistics for mesothelioma would be dramatically different. Research into blood biomarkers (mesothelin, fibulin-3, HMGB1) and liquid biopsy approaches continues to seek viable early-detection strategies.⁶

While staging itself cannot be prevented, earlier detection at lower stages significantly improves treatment options and survival. Strategies to promote earlier diagnosis include:⁶

• Exposure awareness — Individuals with known asbestos exposure should inform all healthcare providers of their exposure history. Any new or persistent respiratory symptoms (chest pain, shortness of breath, cough) in an asbestos-exposed person should be evaluated with mesothelioma as a differential diagnosis.¹
• Prompt symptom evaluation — Avoid attributing new symptoms to aging or common conditions without appropriate diagnostic workup. Recurrent or unilateral pleural effusion in a patient with asbestos exposure history warrants thorough investigation.¹
• Biomarker research — Soluble mesothelin-related peptides (SMRP), fibulin-3, and high-mobility group box protein 1 (HMGB1) are under investigation as blood-based screening biomarkers for mesothelioma. No biomarker has yet achieved sufficient sensitivity and specificity for population-based screening, but they may complement clinical assessment in high-risk populations.⁶
• Primary prevention — The ultimate prevention strategy remains elimination of asbestos exposure through regulatory compliance, professional abatement, and public awareness of asbestos exposure sources.¹